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1. Introduction
Cancer is a leading cause of death worldwide. In 2012, the incidence
of cancer was estimated to be 14 million cases with 8 million cancer-
related deaths (Stewart et al., 2015). 1.7 of the 14 million cases of
cancer in 2012 were cervical cancer with over 500,000 deaths (Torre
et al., 2016). In 2016 approximately 90% of all deaths from cervical
cancer happened in low-income and middle-income countries (Knaul
et al., 2019). The high mortality rate of cervical cancer in low-income
countries is often attributed to lack of access to screening and preven-
tion efforts, not to an inability to provide treatment (Gyawali and
Iddawela, 2016). A large proportion of cervical cancer patients in low-
income countries present at an advanced stage (Sankaranarayanan
et al., 2010) and our cancer treatment program in Haiti, operated by the
non-profit Innovating Health International (IHI), is representative of
this phenomenon. With limited resources, IHI manages a vertically-in-
tegrated approach towards cervical cancer treatment combining a
widespread screening campaign, awareness programs, chemotherapy
and surgery.
Screening is an integral component of reducing the risk of cervical
cancer for women. Low-cost, evidence-based, alternative screening
methods are often applied to limited resource settings. This includes the
single visit approach referred to as the “screen and treat” method, with
uses VIA combined with cryotherapy or thermocoagulation (Ardahan
and Temel, 2011). Of many studies conducted, VIA consistently has a
higher rate of sensitivity when contrasted with Pap smear (Ardahan and
Temel, 2011; Saleh, 2014). Because vaginal HPV swabs are preserved
indefinitely at room temperature and may be shipped from anywhere in
the country to a laboratory there is great potential for this screening
method in low resource settings.
Radiotherapy has been found to benefit at least 50% of all cancer
patients (Atun et al., 2015; International Atomic Energy Agency, 2014)
but little international funding is committed to increasing access in low-
income countries. Limited resources prohibit these countries from im-
plementing radiation due to lack of infrastructure, lack of reliable
electricity, variable security, and geopolitical instability (Barton et al.,
2014). There is a world-wide shortage of radiotherapy with up to 90%
of low-income populations lacking access to these resources (Gajjar
et al., 2018a). Without radiotherapy in Haiti (Gajjar et al., 2018a), IHI
has begun to implement neoadjuvant chemotherapy to expand the
potential for treatment for cervical cancer patients. Chemotherapy is
considered safe in the treatment of cervical cancer and is less expensive
than radiotherapy (Smith and Rutledge, 1975). As of April 2018, the
Dominican Republic retired its last cobalt machine, the use of which
cost $2000 per treatment, per patient. Of note, linear accelerator
treatment costs over $10,000 per patient, far outside the reach of NGOs
and most Haitians.
Studies of neoadjuvant chemotherapy (NACT) have shown success
in implementing cisplatin and paclitaxel as a first line treatment for
advanced stages of cervical cancer (Moore et al., 2004; Electronic
Medicines Compendium: Doxorubicin 2 mg/ml Concentrate for Solution for
Infusion: Summary of Product Characteristics, 2014). NACT with cisplatin
and paclitaxel has the ability to eliminate or shrink the primary tumor
and allow procession to radical hysterectomy (Kim et al., 1989). Many
studies have found NACT to have a response rate of higher than 80%
(Yamaguchi et al., 2012). In one study of 54 patients that received
chemotherapy followed by radical hysterectomy, 81% of patients had a
histological response to treatment and 94% of patients were tumor free
at two years (Kim et al., 1989). One recent meta-analysis consisting of
872 patients showed a 35% mortality risk reduction with the use of
NACT followed by surgical intervention compared to radiation therapy
alone (Neoadjuvant Chemotherapy for Locally Advanced Cervical
Cancer Meta-analysis Collaboration, 2003). This study displayed a 14%
improvement in 5 year survival with a survival rate of 64% for patients
with advanced stages of cervical cancer (Neoadjuvant Chemotherapy
for Locally Advanced Cervical Cancer Meta-analysis Collaboration,
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2003). Based on these studies, new resource-stratified guidelines from
the American Society of Clinical Oncology recommend NACT followed
by hysterectomy for cervical cancer stages II-IV for women in countries
that do not have access to radiotherapy (Chuang et al., 2016a).
There is a great need for further investigation into alternative cer-
vical cancer screening and treatment methods in low resource coun-
tries. The disparity in cervical cancer deaths between low income
countries such as Haiti and the rest of the developed world is alarming.
This report reviews screening and treatment methods at IHI's programs
in Haiti and navigates the components of our vertically-integrated
cervical cancer screening and treatment program. We will describe the
results of three separate components of the program: screening, che-
motherapy, and surgery.
2. Methods
2.1. Screening
IHI and the Haitian Ministry of Health have initiated the “screen
and treat”method at 10 public hospitals throughout Haiti. Additionally,
IHI has implemented an employment-based program using vaginal self-
swabs for high-risk HPV followed by thermocoagulation for those who
test positive (DeGennaro Jr et al., 2015a). This initiative takes place in
factories where women work six days a week across the country. In this
way, screening is brought into the community for women who would
not otherwise have access to care. In both projects, IHI utilizes Haitian
community health workers (CHWs), nurses, and community leaders to
provide health education to these women. Increasing evidence has
shown that education provided by native CHWs is more effective, fos-
ters community engagement and improves health outcomes in rural
areas that lack typical screening and treatment facilities (Glanz et al.,
2008).
For the hospital VIA program, patients completed a basic medical
history form before each exam. The results of exams and follow up visits
were recorded on paper as well. Patient data was collected from each of
the clinics and entered into a secure computer database. Nurses took
photos of the data sheets to ensure proper data entry back at our main
office in Port au Prince. Original paper forms were left at the partner
hospitals.
2.2. Chemotherapy
Since 2013, IHI has trained 32 Haitian physicians and 50 Haitian
nurses in general cancer care from diagnosis to treatment, including the
mixing and administration of chemotherapy. Training includes in-
tensive classroom education on cervical cancer pathophysiology, pre-
sentation, diagnosis, and treatment using chemotherapy treatment al-
gorithms (Santamaria et al., 2016) and training in performing core
needle biopsies. Core biopsies were performed instead of punch biop-
sies because supplies for the latter are not as readily available. We
believe that this substitution does not significantly or negatively impact
patient care. In collaboration with the Ministry of Health, we have
administered chemotherapy at five different hospitals across the
country, although we principally treat at an outpatient cancer center in
Port-au-Prince.
A chart review of our patients with a pathological diagnosis of
cervical cancer from June 1st, 2016 to May 31st, 2018 was performed
and the following key variables were extracted: age, FIGO classifica-
tion, histological type, grading, obstetrical history, contraception use,
tobacco use, HIV status and clinical outcome. These variables were then
evaluated to determine their association with mortality. Tissue was
reviewed in a pathology lab in Port au Prince or Cap Haitien.
Once the diagnosis of cervical cancer was established via biopsy and
local interpretation patients met with Haitian physicians on site for
treatment. Treatment plans were developed depending on cancer stage
and grade. Typically patients received 75mg/m2 cisplatin with or
without 175mg/m2 paclitaxel every three weeks for a total of one to six
cycles depending on FIGO stage and clinical response. Patients were
monitored with CBC and creatinine every three weeks. Patient in-
formation was recorded upon consultation and throughout treatment.
After completion of treatment, patient information was entered into a
computerized file system.
2.3. Radiation therapy
Occasionally, NGOs such as IHI, are able to assist a small number of
patients to receive radiotherapy in the Dominican Republic (Santamaria
et al., 2016). Out of the152 patients seen the past two years at IHI for
cervical cancer, only three were able to receive radiation therapy.
Unfortunately, not all were able to complete treatment due to cost and
logistics.
2.4. Surgery
IHI has successfully organized five surgical trips during which for-
eign gynecologic oncologists traveled to Haiti to train and operate with
Haitian OB GYNs. Ideal patient criteria to be eligible for surgery in-
cluded having stage IB2, II or III cervical cancer, having completed at
least three cycles of NACT and having a hemoglobin > 9 g/dL at the
time of operation. Ideally all patients with stage 2 or 3 cancer would
have gotten at least 3 cycles of NACT before surgery. There were 3
exceptions in which patients received only 1–2 cycles of NACT, usually
due to timing of when surgical teams would be in country. If deemed
resectable at that time, they proceeded to surgery. Others with IB2
didn't warrant chemotherapy according to our protocol, but received it
as a means of temporizing the cancer while we waited up to three
months for a surgical team to come. After careful review of each pa-
tient's case and the risks/benefits the decision was made to proceed
with surgery in the interest of the patient. Patients were monitored in
the postoperative period by our IHI OB GYNs, both immediately and for
follow up. They communicated by telephone or text with the visiting
surgeon as needed. Two Haitian OB GYNs consistently operated with
the visiting surgeons, with the goal of training them to perform radical
hysterectomies independently. The project is ongoing. There are very
few Haitian OB GYNs who are trained to perform radical hyster-
ectomies, especially when the indication is for malignancy. The inten-
tion of this program was to provide this training while treating patients.
The Haitian OB GYNs chosen to be involved in this program have fin-
ished residency, studied oncology with IHI, and have been adminis-
tering chemotherapy for 3 years as part of IHI's cancer treatment pro-
gram. They are the OB GYNs with the most oncology training in the
country who expressed an interest in advancing their surgical skills.
Providing them with an opportunity to learn radical hysterectomy has
the potential to substantially impact patient care. The goal is to have
each surgeon perform at least 25 operations before working in-
dependently.
3. Results
3.1. Screening program
A retrospective review of data from IHI and its partner facilities
indicates that 4556 patients have undergone the VIA “screen and treat”
method over a 2-year period ending in June 2018. Of those, 840 women
(18.4%) were positive and treated with cryotherapy or thermo-
coagulation. This percentage is similar to other studies in low income
settings. One such study in India found a VIA positivity rate of 10.75%
(Poli et al., 2015). The average age of patients seen in clinic for the “see
and treat” method was 38.9 years old. Through this program, 59 Hai-
tian nurses/midwives and 10 Haitian physicians have been trained in
the “see and treat” method with cryotherapy or thermocoagulation.
Patients with lesions covering< 75% of the cervix and without
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endocervical involvement were eligible for thermocoagulation. Ther-
mocoagulation was typically performed by our trained IHI nurses. If the
patient had a lesion>75% of the cervix or there was extension into
endocervix, they were referred to an IHI OB GYN for performance of a
LEEP.
As part of our awareness program, 33,258 people were educated on
cervical cancer through in-person outreach events. This included lec-
tures given by CHWs and cancer survivors at churches and schools and
volunteers going door to door in their neighborhoods. There is no way
to quantify the number of people reached through television and radio
interviews as well as social media outreach, but it likely doubles that
which we were able to reach in person.
3.2. Chemotherapy program
A total of 152 cases of cervical cancer were managed during the
study period. 6.6% of them were recurrent malignancies. The median
age of the study population was 52.5 years old with a range of
30–90 years old (Table 1). 10.5% (n=143) of the patients admitted to
tobacco use. 62.8% of the women (n= 145) were post-menopausal and
37.9% (n= 145) had a history of abortion. Of those with known HIV
status (n= 78), 15.4% were seropositive. Of those patients with FIGO
classification recorded (n=126), 80.1% were Stage IIB or higher, and
29.3% were Stage IV. Tissue pathology varied with 83.3% invasive
squamous cell carcinoma, 9.5% adenocarcinoma, 6.3% in situ squa-
mous carcinoma and 0.8% adenosquamous carcinoma. The overall
mortality rate was 25.7% over 24months, and 10.5% of the patients
were lost to follow-up. Much like in our breast cancer program, we have
not had any serious complications related to giving chemotherapy, in-
cluding those who are HIV program (DeGennaro Jr et al., 2015b).
Of the advanced cases of cervical cancer, 17 patients received
neoadjuvant chemotherapy with cisplatin and paclitaxel before a
planned radical hysterectomy, 2 received chemoradiation therapy
outside of Haiti, 31 received palliative chemotherapy with cisplatin
only and 46 received palliative care only (Fig. 1).
3.3. Surgery program
A total of 16 patients were identified as eligible for surgery and
brought to the operating room. Of them, 7 had a radical hysterectomy,
6 had simple hysterectomies, and 3 were open and close procedures due
to obvious metastatic disease (Table 2). All those who underwent hys-
terectomy were thought to have clinically negative margins. Simple
hysterectomy is considered the standard of care for stage IB2 patients in
low income countries per ASCO guidelines (Wu et al., 2017; Chuang
et al., 2016b). We had 2 patients with cancer beyond IB2 who had
simple hysterectomies (IIA and IIB). The decision of simple versus ra-
dical hysterectomy was ultimately made by the surgeon based on pre-
ference and patient safety. 25 of our patients had stage IIA or less. These
patients were referred out to other community OB GYNs who are cap-
able of doing simple hysterectomies. We did not continue to follow
them clinically.
The most recent two surgical trips comprised 11 of the 16 total
procedures, indicating that the program is growing in efficiency and
that the need for radical hysterectomies post-NACT is apparent in this
community. One intraoperative complication, damage to the inferior
vena cava and left common iliac vein, occurred. All patients were alive
at least 12months from the date of their operation with no post-op-
erative complications, and we will continue to follow them. Evidence of
disease is determined clinically since routine CT scans are too expensive
for the program's resources. One patient who had obvious metastases
noted in surgery was still living 12months later without other inter-
ventions. Deciding whether there is evidence of disease after treatment
is determined clinically in follow up.
4. Discussion
In low-resource settings, providers are challenged to adapt cost-ef-
fective and culturally competent methods of delivering healthcare. We
have presented a vertically-integrated model for cervical cancer pre-
vention, screening and treatment in Haiti. At each phase of our pro-
gram, we have made adaptations from the typical methods available in
high and middle-income countries. We have encountered countless
barriers, chief among them being cost. IHI never refuses to care for a
patient due to lack of finances. Because improving access to quality care
Table 1
Baselines characteristics of the study population.
Variables Frequency (n) Proportion (%) 95% Confidence
Interval
Age at Presentation
(N=152)
30–39 17 11.2% 6.7%–17.3%
40–49 45 29.6% 22.5%–37.5%
50–59 44 28.9% 21.9%–36.9%
60–69 28 18.4% 12.6%–25.5%
70–79 13 8.6% 4.6%–14.2%
≥80 5 3.3% 1.1%–7.5%
Stage at Presentation
(N=126)
0 (In situ carcinoma) 8 6.3% 2.8%–12.1%
IA 1 0.8% 0.02%–4.3%
IA1 1 0.8% 0.02%–4.3%
IB1 4 3.2% 0.9%–7.9%
IB2 5 4.0% 1.3%–9.0%
IIA 6 4.8% 1.8%–10.1%
IIB 20 15.9% 10.0%–23.4%
IIIA 29 23.0% 16.0%–31.4%
IIIB 15 11.9% 6.8%–18.9%
IVA 29 23.0% 16.0%–31.4%
IVB 8 6.3% 2.8%–12.1%
Risk Factors
Tobacco use (N=143) 15 10.5% 6.0%–16.7%
History of abortion
(N=145)
55 37.9% 30.0%–46.4%
Teenage pregnancy
(N=78)
39 50.0% 38.5%–61.5%
Children with > 1 man
(N=84)
57 67.9% 56.8%–77.6%
Family history of cancer
(N=97)
18 18.6% 11.4%–27.7%
Baseline ECOG (N=113)
0 92 81.4% 73.0%–88.1%
1 14 12.4% 6.9%–19.9%
2 4 3.5% 0.97%–8.8%
3 1 0.9% 0.02%–4.8%
4 2 1.8% 0.2%–6.2%
HIV status (N=152)
HIV-positive 12 7.9% 4.1%–13.4%
HIV-negative 66 43.4% 35.4%–51.7%
Unknown 74 48.7% 40.5%–56.9%
Recurrent case (N=152)
Yes 10 6.6% 3.2%–11.8%
No 142 93.4% 88.2%–96.8%
Histologic subtype
(N=126)
Squamous cell
carcinoma
105 83.3% 75.7%–89.4%
Adenocarcinoma 12 9.5% 5.0%–16.1%
In situ carcinoma 8 6.3% 2.8%–12.1%
Adenosquamous
carcinoma
1 0.8% 0.02%–4.3%
Histologic grading
(N=90)
Grade 1 21 23.3% 15.1%–33.4%
Grade 2 53 58.9% 48.0%–69.2%
Grade 3 16 17.8% 10.5%–27.3%
Outcome (N=152)
Alive/in treatment 98 64.5% 56.3%–72.1%
Deceased 38 25.0% 18.3%–32.7%
Lost to follow-up 16 10.5% 6.1%–16.5%
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is our ultimate goal, we individualize services based on the patient si-
tuation, which may include coverage for things such as transportation
to the clinic, nutrition and clothing. Only approximately 25% of our
treatment costs come from patient payments.
Our cohort of women with cervical cancer undergoing che-
motherapy was relatively young, with 40.8%<50 years of age. The
prevalence of tobacco use (10.5%) in this population was more than
twice that of Haitian women in general and nearly twice that of tobacco
use in Haitian women with breast cancer (DeGennaro Jr et al., 2018a;
DeGennaro Jr et al., 2018b). The prevalence of HIV in this population
was 15.4%, much higher than the overall HIV prevalence in Haiti of
2.1% (Unicef, 2013). While most women had Stage III or IV cancer
(64.2%), 93.8% were highly functional with an ECOG of 0 or 1.
Training Haitian staff continues to be the highest priority in all of
our programs. At this point, only the surgical program requires outside
specialists. The majority of people involved in our program live in Haiti
and are fluent in Creole. We are an intimate part of the community and
culture. For our incoming surgeons, we have translators available for
the operating room as needed and the OB GYNs speak English. The head
nurse of our screening program travels to the all of the sites to ensure
the quality of VIA and thermocoagulation/cryotherapy treatments. This
portion of the program has been nurse-led for 3 years, they are well
trained, and task shifting is quite common and indeed necessary in low-
income settings. The head nurse helps with raising local awareness of
the program and works in the community with the ultimate goal being
independent support of the program. There is high turnover of nursing
staff at Haitian hospitals, which has been a challenge. We have had to
train new staff members in VIA with cryotherapy or thermocoagulation
at two of the partner hospitals. We are also currently training another
Haitian internist in oncology. Her education involves a mix of didactics,
supervised patient encounters, and telemedicine.
Data collection, entry and management has been a challenge for our
screening program. Because each site is a public hospital, we have tried
not to implement onerous, new documentation requirements. In the
future, we hope to use optical character recognition (OCR) capture
software to speed data entry, improve data fidelity, and lower nursing
travel costs. Our onsite nurses typically have smartphones and could
potentially upload images of clinical patient forms using OCR tech-
nology. This would both lower costs associated with nurse visits to sites
simply to collect data and increase data accuracy.
Supply chain management is another constant challenge in this
program. Nurses at many of our sites do not have access to computers
and must rely on non-electronic forms of inventory control. OCR forms
for inventory would allow them to use pencil and paper and then
capture and send the image to the coordinating team in Port au Prince
without the need for a computer. In addition, we have started to pro-
cure all supplies in large volumes for six-month blocks to decrease cost,
reduce manpower for procurement, and ensure adequate stock.
Fig. 1. Patient flow chart.
Table 2
Characteristics of surgical cases.
Patient Age Histology Pre-op
stage
Cycles of
NACT
Procedure performed
1 47 SCC cervix IIB 2 Type III radical hysterectomy, BSO, LND
2 56 SCC cervix IIIA 3 Open and close, metastasis in omentum and right pelvis
3 56 SCC cervix IIB 2 Simple hysterectomy with small upper vaginal margin, BSO, LOA
4 62 Adenocarcinoma cervix IIB 6 Metastasis noted, R salpingo-oophorectomy for pathology
5 68 SCC cervix IIB 5 Type II modified radical hysterectomy, BSO, LOA
6 63 SCC cervix II 3 Open and close due to metastasis
7 54 SCC cervix IIIA 3 Wetheim-Meigs operation (Querleu C), bilateral pelvic and retroperitoneal lymphadenectomy, IVC
injury, Left Common Iliac Vein Injury
8 49 SCC IIIA 4 Wetheim-Meigs operation (Querleu B2), bilateral pelvic and retroperitoneal lymphadenectomy
9 31 SCC IIIA 3 Wetheim-Meigs operation, bilateral pelvic and retroperitoneal lymphadenectomy, mass in left iliac
vessels, lymph nodes in retroperitoneum
10 74 SCC IIIA 6 Wetheim-Meigs operation (Querleu C) and bilateral pelvic lymphadenectomy
11 62 SCC IIA 3 Simple hysterectomy
12 61 SCC IIIA 1 Wetheim-Meigs operation (Querleu C) and bilateral pelvic and retroperitoneal lymphadenectomy
13 53 SSC IB2 3 Simple hysterectomy, LND
14 46 Papillary adenocarcinoma IB2 3 Simple Hysterectomy, LND
15 45 SCC IB2 3 Simple Hysterectomy, LND
16 55 SCC IIB 3 Simple Hysterectomy, LND
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As is the case with much of global health, our chemotherapy pro-
tocols were partly determined based on availability of resources. For
example, carboplatin is significantly more expensive than cisplatin and
has largely been substituted. In patients who were staged clinically
before and after chemotherapy, there was an overall decrease in their
stage. Unfortunately, our sample size is too small to determine statis-
tical significance in improvement of tumor burden or operability after
chemotherapy.
The American surgeons who have participated in our program have
come from both private and academic settings, allowing for a diversity
of training in operative approaches for our Haitian OB/GYNs. We are
currently testing adoption of standard US operating room practices such
as pre-operative check lists, standard operating procedures, case logs,
and other items to ensure quality surgical and anesthesia care.
Perhaps the most important aspect of our program is the vertical
integration of screening, chemotherapy and surgery. Haiti has a frag-
mented healthcare system that is difficult to navigate for those with an
education and means but can be literally impossible for those who are
uneducated and poor. By referring patients directly from IHI-partnered
screening sites to the IHI Women's Cancer Center, we decrease loss to
follow up and can offer care to those who cannot afford it.
5. Conclusion
Awareness campaigns, “see and treat” screening methods, and col-
laborations with public institutions have all helped IHI develop a ver-
tically-integrated cervical cancer program. Due to these efforts there
has been a significant increase in patients seeking screening and
treatment. As screening and treatment for cervical cancer increases, the
hope is to make more treatment methods available in the future. Of
note, we have an analogous initiative for breast cancer, which has had
great success (DeGennaro Jr et al., 2018a; Gajjar et al., 2018b;
DeGennaro Jr et al., 2015b). IHI is hopeful that likewise this developing
program will bring new opportunities for cancer care in low-income
countries.
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